Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Medtronic-Sponsored Economic Analysis Supports CRT Devices As Cost-Effective

Executive Summary

New analysis from the Medtronic-sponsored REVERSE trial shows that patients with mild heart failure receiving CRT therapy had an ICER (incremental cost effectiveness ratio) of $8,840 per QALY, compared to those not receiving CRT.


Related Content

More Patients Should Receive Cardiac Resynchronization Therapy, Heart Groups Say
Boston Scientific Gains Expanded Indication For CRT-D Devices
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst